

Special Issue

Protective Immunity and Adjuvant Vaccines

Message from the Guest Editor

This Special Issue focuses on the significance of investigating antigen–adjuvant interactions, summarizing research on commonly used adjuvant formulations such as aluminum salts, emulsions, lipid vesicles, and polymer-based particles. The Special Issue emphasizes the importance of understanding the physical and chemical basis of antigen–adjuvant associations, utilizing appropriate analytical tools for their characterization, and discussing how these interactions impact vaccine effectiveness. We invite comprehensive research and reviews that explore the following topics: We welcome research and reviews on:

- Mechanisms of protective immunity: understanding innate and adaptive responses, memory B and T cells, and cross-protective immunity.
- Adjuvant vaccine development: innovations in adjuvant design, formulations, and comparative efficacy studies.
- Clinical and preclinical adjuvant studies
- Molecular and cellular pathways activated by adjuvants.
- Public health implications, outbreak response, and cost-effectiveness.
- Innovative approaches: bioinformatics, personalized vaccines, and novel adjuvants.

Guest Editor

Prof. Dr. Chengli Zong

School of Pharmaceutical Sciences, Hainan University, Haikou, China

Deadline for manuscript submissions

31 December 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/213438

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).